US2023255940A1PendingUtilityA1

Oxymetazoline for the treatment of ano-rectal disorders

Assignee: RDD PHARMA LTDPriority: Apr 26, 2011Filed: Apr 25, 2023Published: Aug 17, 2023
Est. expiryApr 26, 2031(~4.8 yrs left)· nominal 20-yr term from priority
A61K 31/4174A61K 9/0031A61K 45/06A61K 31/4164A61P 1/00A61P 21/00A61P 43/00A61K 31/451A61K 31/485
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method,
 wherein the method treats fecal incontinence in a subject in need thereof,   wherein the method comprises: administering a therapeutically effective amount of a composition comprising oxymetazoline or a pharmaceutically acceptable salt thereof to the subject's anal cavity, to treat the fecal incontinence,   wherein the therapeutically effective amount of the composition comprises 0.1% to 1% of oxymetazoline or a pharmaceutically acceptable salt thereof.   
     
     
         2 . The method of  claim 1 , wherein the composition comprises oxymetazoline hydrochloride. 
     
     
         3 . The method of  claim 1 , wherein the composition further comprises at least one carrier, diluent, excipient, or combinations thereof. 
     
     
         4 . The method of  claim 1 , wherein the composition is selected from the group consisting of: long acting, controlled release, slow release, sustained release, bioadhesive and mucoadhesive. 
     
     
         5 . The method of  claim 1 , wherein the composition is in a dosage form selected from the group consisting of: gel, cream, paste, spray suppository, mousse, emollient, powder, solution, suspension and foam. 
     
     
         6 . The method of  claim 1 , wherein the therapeutically effective amount of the composition comprises 0.08% to 0.8% of oxymetazoline or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method of  claim 1 , wherein the therapeutically effective amount of the composition comprising oxymetazoline or a pharmaceutically acceptable salt thereof is sufficient to treat fecal incontinence in the subject for at least 4 hours.

Join the waitlist — get patent alerts

Track US2023255940A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.